Andreeva Marina

MD, Assistant of the Department of Neurological and Neurosurgical Diseases
Belarussian State Medical University, Minsk, Belarus
Andreeva Marina
Andreeva Marina, MD, is assistant professor of the department of neurological and neurosurgery diseases Belarussian state medical university, neurologist, scientific fellow worker in laboratory of information and computer technology of University research division.
She graduated from Belarussian state medical university in 2010. Since 2015 holds the position of assistant chair in department and carries out scientific and clinical activities in Minsk scientific and practical center of surgery, transplantology and hematology. Investigator in clinical center for randomized clinical trials for multiple sclerosis disease modifying therapy (DMT). Research interest is multiple sclerosis progression risk prediction during DMT, including stem cells therapy, development of automated analysis systems for demyelinisation foci dynamics within neuroimaging monitoring.
Stem Cell Therapy for Multiple Sclerosis in Belarus
Current State - Output - Perspective
Sharing the Experience at International Conference in Moscow, Russia, November 2019
The stages of the development of stem cells therapy for the use in multiple sclerosis (MS) patients in Belarus are being considered. The approaches to patients' selection, rationale and types of stem cells therapy - autologous hematopoietic stem cell transplantation, со- transplantation of hematopoietic and mesenchymal stem cells, retransplantation of mesenchymal stem cells - are being discussed. The use of both conditioning regimens - BEAM and ATG + CF + MP - demonstrated good safety and tolerability. The technology of со- transplantation of hematopoietic and mesenchymal stem cells was more effective than autologous hematopoietic stem cell transplantation for MS patients according to changes of neurologic status at 6 months after transplantation (p <0.05). The study of the long-term consequences of autologous stem cell
transplantation in patients with MS revealed that the use of this technology allows to achieve longterm stabilization of clinical and neurological parameters.

For the first time, significant factors for predicting the effectiveness of transplantation in patients with MS have been revealed — the ratio of dose of injected cells / patient weight, the level of previous disability on the EDSS scale and the duration of the stable state before transplantation affect the duration of the stable period after transplantation. The analysis of the optic cogerent tomography data suggests that transplantation of mesenchymal stem cells can promote remyelination of the neural tissue in patients with a relapsing-remitting form of MS.
Marina Andreeva
Belarussian State Medical University, Minsk, Belarus